Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Pentostatin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Pentostatin.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pentostatin.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Pentostatin is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pentostatin.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Pentostatin is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Pentostatin is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Pentostatin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Pentostatin.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pentostatin.
Clozapine
The risk or severity of adverse effects can be increased when Pentostatin is combined with Clozapine.
Cyclophosphamide
Pentostatin may increase the cardiotoxic activities of Cyclophosphamide.
Cyclophosphamide Anhydrous
Pentostatin may increase the cardiotoxic activities of Cyclophosphamide.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Pentostatin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Pentostatin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Pentostatin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Pentostatin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Pentostatin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.
Fingolimod
Pentostatin may increase the immunosuppressive activities of Fingolimod.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Pentostatin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pentostatin is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Pentostatin is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Pentostatin is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.
Nelarabine
Pentostatin may decrease the antineoplastic activities of Nelarabine.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Pentostatin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Pentostatin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pentostatin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pentostatin.
Pegademase Bovine
The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase bovine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pentostatin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Pentostatin.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Pentostatin is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pentostatin.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Pentostatin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Pentostatin is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Pentostatin is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Pentostatin is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pentostatin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pentostatin.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Pentostatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Pentostatin may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Pentostatin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Pentostatin is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Pentostatin is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Pentostatin is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Pentostatin is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Pentostatin is combined with Yellow Fever Vaccine.
